ContraVir Pharmaceuticals to Present at 2017 Marcum MicroCap Conference

20:00 EDT 7 Jun 2017 | Globe Newswire

EDISON, N.J., June 08, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at The 2017 Marcum MicroCap Conference being held June 15-16, 2017, at the Grand Hyatt New York in New York City.

James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Mr. Sapirstein was also invited to participate on a panel discussing the topic, "Identifying Breakthrough Opportunities in Life Sciences."

Event:ContraVir Company Presentation
Date: Thursday, June 15, 2017
Time: 10:30 AM – 10:55 AM (Eastern Time)
Location:Broadway - Conference Level
Webcast Details:
The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the investor relations section of the ContraVir website at
Event:Panel: Identifying Breakthrough Opportunities in Life Sciences
Date: Thursday, June 15, 2017
Time: 04:00 PM – 05:00 PM (Eastern Time)

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2a, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). For more information visit

For further information, please contact: 
Sharen Pyatetskaya 
Director of Investor Relations; (732) 902-4028

Primary Logo


More From BioPortfolio on "ContraVir Pharmaceuticals to Present at 2017 Marcum MicroCap Conference"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...